A Phase 3 interventional study of Baloxavir Marboxil and Oseltamivir in Influenza, sponsored by Hoffmann-La Roche. Completed at 16 sites in China. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.
Among the 18 studies testing baloxavir in Influenza, Human, this one is the 16th largest by enrollment, is one of 2 that started in 2024, is one of 12 in phase 3, and was the 16th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Unity Health Toronto · Sites in Canada
Ages 18+
Dre Pauline Vetter · Sites in Switzerland
Ages 18+
Hoffmann-La Roche · Sites in United States, Bulgaria, Poland and 1 more country
Ages 3 wk–11 yrs
University of Oxford · Sites in Brazil, Laos, Nepal and 1 more country
Ages 18–60
By country, each count listing its studies:
baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 1 Year to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 13 · Phase 4 3
First in 2016; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is below the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 483 across the 18 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
22 studies in Influenza, Human by Hoffmann-La Roche: 2 open now, 2 under way, 2 of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 22 studies in Influenza, Human by Hoffmann-La Roche, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is one of 10 in phase 3, and was the 21st registered.
Hoffmann-La Roche’s Influenza, Human studies by the year they started, since 2006.
5 of the studies testing baloxavir in Influenza, Human that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314905Phase 3Unity Health TorontoAdaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | 2027-03-31 |
| NCT06653569Phase 3Dre Pauline VetterEfficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment) | 2027-04 |
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT05648448University of OxfordA Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza | 2027-01-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies testing baloxavir in Influenza, Human, from their registry updates:
Among Hoffmann-La Roche’s 22 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety of a single dose baloxavir marboxil compared with 5 days of oseltamivir administered twice a day (BID) in Chinese pediatric participants aged 1 to \< 12 years with influenza symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A participant who has a diagnosis of influenza virus infection and meets all the following conditions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of baloxavir marboxil on Day 1 based on body weight.
Drug: Baloxavir Marboxil
Participants will receive oseltamivir twice a day for 5 days based on body weight.
Drug: Oseltamivir
Baloxavir marboxil will be administered as oral suspension: 2 milligrams per kilograms (mg/kg) (if weight \< 20 kg), 40 mg (if weight ≥ 20 kg to \< 80 kg), or 80 mg (if weight ≥ 80 kg).
Oseltamivir will be administered as oral capsule: 30 mg (if weight ≤15 kg), 45 mg (if weight \> 15 kg to ≥ 23 kg), 60 mg (if weight \> 23 kg to ≤ 40 kg) or 75 mg (if weight \> 40 kg), twice daily (BID) for 5 days.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability or incapacity, was a congenital anomaly or birth defect.
Time frame: Up to Day 29
Time to Alleviation of Influenza Signs and Symptoms (TTAS)
TTAS was defined as the length of time taken from start of treatment to point at which all of following criteria were met \& remained so for at least 21.5 hours: * Score of 0 (no problem) or 1 (minor problem) for cough \& nasal symptoms (Items 14 \& 15 of Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]); * A "yes" response to following question- "Since last assessment has participant been able to return to day care/school, or resume his/her normal daily activity in same way as performed prior to developing flu?"; * Return to afebrile state (tympanic temperature ≤ 37.2 degree Celsius \[°C\]). Median time was estimated using Kaplan-Meier (K-M) method.
Time frame: Up to Day 15
Duration of Fever
Duration of fever was defined as the length of time from start of treatment to return to afebrile state (tympanic temperature ≤ 37.2°C) and remaining so for at least 21.5 hours. Participants who were afebrile at baseline (tympanic temperature ≤ 37.2 °C) or whose body temperature was not collected were excluded from the analysis. Median time was estimated using K-M method.
Time frame: Up to Day 15
Duration of Symptoms
Duration of symptoms was defined as the length of time from start of treatment to alleviation of all symptoms as defined by a score of 0 (no problem) or 1 (minor problem) and remaining so for at least 21.5 hours, for all 18 symptoms specified in the CARIFS questionnaire. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point. Median time was estimated using K-M method.
Time frame: Up to Day 15
Time to Return to Normal Health and Activity Based on the CARIFS Questionnaire
Time to return to normal health and activity was defined as time from start of treatment to normal health and activity. Normal health \& activity was identified by a 'yes' response to the following question on the CARIFS: "Since the last assessment has the participant been able to return to day care/school, or resume his/her normal daily activity in the same way as performed prior to developing the flu?". Median time was estimated using K-M method.
Time frame: Up to Day 15
Number of Participants With Influenza-related Complications
Influenza-related complications included death, hospitalization, radiologically-confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, and myositis.
Time frame: Up to Day 29
Percentage of Participants Requiring Antibiotics for Influenza-related Complications
Influenza-related complications included death, hospitalization, radiologically-confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, and myositis. Percentages have been rounded off.
Time frame: Up to Day 29
Time to Cessation of Viral Shedding by Virus Titer
Time to cessation of viral shedding by virus titer was defined as the time, in hours, between the initiation of study treatment and the first time when the influenza virus titer was below the lower limit of detection (LLoD) (0.75 log10 tissue culture infectious dose \[TCID\] 50/milliliters \[mL\]). Participants whose virus ribonucleic acid (RNA) did not reach the limit by the last observation timepoint were treated as censored at that timepoint. Median time was estimated using K-M method.
Time frame: Up to Day 29
Time to Cessation of Viral Shedding by Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) Using Samples From Respiratory Swabs
Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of study treatment and the first time when the virus RNA by RT-PCR qualitative result is below the LLoD (qualitative assessment). For the participants with multiple virus types, time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA by RT-PCR qualitative result is negative for all virus types. Participants whose virus RNA did not reach the limit by the last observation timepoint were censored at that timepoint. Median time was estimated using K-M method.
Time frame: Up to Day 29
Change From Baseline in Influenza Virus Titer Over Time Using Samples From Respiratory Swabs
Change from baseline in influenza virus titer (log10 TCID50/mL) on Days 2, 4, 6, 10, and 15 are presented. Influenza virus titer on specified time points was analysed with use of samples from respiratory swabs. If influenza virus titer was less than the lower limit of quantification (LLoQ), the virus titer was imputed as LLoQ - 0.001 (0.749 log10 TCID50/mL). Only participants with a positive virus titer on Day 1 were included in this analysis.
Time frame: Baseline, Days 2, 4, 6, 10, and 15
Change From Baseline in Amount of Virus RNA (RT-PCR) at Each Timepoint Using Samples From Respiratory Swabs
If the amount of virus RNA was less than the LLoQ, the amount of virus RNA was imputed as LLoQ - 0.001 (2.79 log10 vp/mL for influenza A and 2.63 log10 vp/mL for influenza B). If a participant was infected with multiple virus types, the sum of those amounts of virus RNA was used for analysis. Participants positive for virus RNA by RT-PCR on Day 1 were included in this analysis. log10 vp/mL=log 10 virus particles per milliliter.
Time frame: Baseline, Days 2, 4, 6, 10, and 15
Percentage of Participants With Positive Influenza Virus Titer Over Time
Percentage of participants with positive influenza virus titer was defined as the percentage of participants whose influenza virus titer was not less than the LLoD (0.75 log10 TCID50/mL) or positive among those assessed for influenza virus titer on specified timepoints. Analyses were done with use of samples from respiratory swabs. Participants with a positive influenza virus titer on Day 1 were be included in this analysis. Percentages have been rounded off.
Time frame: Baseline, Days 2, 4, 6, 10, and 15
Percentage of Participants Positive by RT-PCR at Each Timepoint Using Samples From Respiratory Swabs
Percentage of participants with positive influenza virus titer was defined as the percentage of participants with a positive qualitative result among those assessed by RT-PCR on specified timepoints. Analyses were done with use of samples from respiratory swabs. Participants positive for virus RNA by RT-PCR on Day 1 were be included in this analysis. Percentages have been rounded off.
Time frame: Baseline, Days 2, 4, 6, 10, and 15
Area Under the Curve (AUC) in Virus Titer
AUC was calculated using the trapezoidal method. Participants with a positive virus titer on Day 1 were included in this analysis. The lower limit was defined as 0.75 log10 TCID50/mL for flu A and flu B. If a participant was infected with multiple virus types, the sum of those virus titers was used for analysis. log10 TCID50/mL\*h=log10 TCID50 per milliliter-hours. Analyses were done with use of samples from respiratory swabs.
Time frame: Up to Day 10
AUC in the Amount of Virus RNA (RT-PCR) Using Samples From Respiratory Swabs
AUC in virus RNA (RT-PCR) AUC was calculated using the trapezoidal method. Participants positive for virus RNA by RT-PCR on Day 1 were included in this analysis. If a participant was infected with multiple virus types, the sum of the amount of virus RNA was used for analysis. log10 vp/mL\*h=log 10 virus particles per milliliter-hours.
Time frame: Up to Day 10
Plasma Concentrations of S-033447 (Active Metabolite)
S-033447 is an active metabolite of baloxavir marboxil.
Time frame: Post-dose on Days 1, 2, 4, and 6
Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) of S-033447
S-033447 is an active metabolite of baloxavir marboxil.
Time frame: Post-dose on Days 1, 2, 4, and 6
Maximum Observed Concentration (Cmax) of S-033447
S-033447 is an active metabolite of baloxavir marboxil.
Time frame: Post-dose on Days 1, 2, 4, and 6
Time of Maximum Observed Concentration (Tmax) of S-033447
S-033447 is an active metabolite of baloxavir marboxil.
Time frame: Post-dose on Days 1, 2, 4, and 6
Elimination Half-life (t1/2) of S-033447
S-033447 is an active metabolite of baloxavir marboxil.
Time frame: Post-dose on Days 1, 2, 4, and 6
Percentage of Participants With Polymorphic and Treatment-emergent Amino Acid Substitutions in the Polymerase Acidic (PA) Gene
Sanger sequencing of the influenza PA gene was performed to evaluate the incidence of polymorphic and treatment-emergent amino acid substitutions in baloxavir-treated participants with evaluable virus.
Time frame: Up to Day 29
Drug Susceptibility in Participants With Evaluable Virus
Drug susceptibility of the influenza virus, the 50% effective concentration (EC50) of baloxavir was measured by the ViroSpot™ assay using baseline swab samples for participants who received baloxavir marboxil. EC50 values were compared with EC50 values of reference strains and the respective ratio (EC50 / EC50 reference) was reported. The following influenza virus vaccines strains from the 2024/25 Northern hemisphere season were used as references: A/Wisconsin/67/2022 (H1N1) pdm09-like virus, A/Massachusetts/18/2022 (H3N2)-like virus and B/Austria/1359417/2021-like virus (B/Victoria/2/87 lineage). In the absence of established thresholds for baloxavir, reduced susceptibility was defined according to the WHO criteria for neurainidase inhibitor (NAI) as fold-changes in EC50 (EC50 / EC50 of reference) \> 10 for influenza A and \> 5 for influenza B viruses.
Time frame: Up to Day 29
Percentage of Participants With Responses to Palatability and Acceptability Questionnaire
A two-question palatability and acceptability questionnaire was used to record palatability and acceptability. Palatability of baloxavir marboxil was evaluated by response to the following question, "How was the taste of the medicine? Please pick the face that best matches how you/the child felt about the taste". The responses ranged from: like very much, like a little, not sure, dislike a little, or dislike very much. Acceptability of baloxavir marboxil was evaluated by response to the following question, "Would you/the child be happy to take the medicine again?" The responses ranged from: Yes, No, or Not sure. The questionnaire was completed as soon as possible after swallowing the baloxavir marboxil drug solution on Day 1. Percentages have been rounded off.
Time frame: On Day 1
A total of 100 participants aged 1 to \<12 years with influenza symptoms were randomized in the study at 16 investigative sites in China from 27 October 2024 to 08 May 2025.
| Milestone | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Started | 67 | 33 |
| Safety analysis set (sas) | 66 | 33 |
| Full analysis set-infected participants (fasi) | 61 | 31 |
| Completed | 64 | 32 |
| Not completed | 3 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Reason not specified | 0 | 1 |
An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability or incapacity, was a congenital anomaly or birth defect.
| Participants | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| AEs | 24 | 12 |
| SAEs | 2 | 0 |
TTAS was defined as the length of time taken from start of treatment to point at which all of following criteria were met \& remained so for at least 21.5 hours: * Score of 0 (no problem) or 1 (minor problem) for cough \& nasal symptoms (Items 14 \& 15 of Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]); * A "yes" response to following question- "Since last assessment has participant been able to return to day care/school, or resume his/her normal daily activity in same way as performed prior to developing flu?"; * Return to afebrile state (tympanic temperature ≤ 37.2 degree Celsius \[°C\]). Median time was estimated using Kaplan-Meier (K-M) method.
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Time to Alleviation of Influenza Signs and Symptoms (TTAS) | 126.1 (92.2 to 141.1) | 119.5 (90.5 to 160.0) |
Duration of fever was defined as the length of time from start of treatment to return to afebrile state (tympanic temperature ≤ 37.2°C) and remaining so for at least 21.5 hours. Participants who were afebrile at baseline (tympanic temperature ≤ 37.2 °C) or whose body temperature was not collected were excluded from the analysis. Median time was estimated using K-M method.
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Duration of Fever | 28.3 (23.3 to 38.9) | 36.1 (29.3 to 44.0) |
Duration of symptoms was defined as the length of time from start of treatment to alleviation of all symptoms as defined by a score of 0 (no problem) or 1 (minor problem) and remaining so for at least 21.5 hours, for all 18 symptoms specified in the CARIFS questionnaire. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point. Median time was estimated using K-M method.
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Duration of Symptoms | 43.9 (35.0 to 76.6) | 51.9 (34.5 to 71.0) |
Time to return to normal health and activity was defined as time from start of treatment to normal health and activity. Normal health \& activity was identified by a 'yes' response to the following question on the CARIFS: "Since the last assessment has the participant been able to return to day care/school, or resume his/her normal daily activity in the same way as performed prior to developing the flu?". Median time was estimated using K-M method.
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Time to Return to Normal Health and Activity Based on the CARIFS Questionnaire | 126.0 (81.8 to 137.8) | 115.3 (88.4 to 136.7) |
Influenza-related complications included death, hospitalization, radiologically-confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, and myositis.
| Participants | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Number of Participants With Influenza-related Complications | 2 | 0 |
Influenza-related complications included death, hospitalization, radiologically-confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, and myositis. Percentages have been rounded off.
| percentage of participants | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Percentage of Participants Requiring Antibiotics for Influenza-related Complications | 1.6 | 0 |
Time to cessation of viral shedding by virus titer was defined as the time, in hours, between the initiation of study treatment and the first time when the influenza virus titer was below the lower limit of detection (LLoD) (0.75 log10 tissue culture infectious dose \[TCID\] 50/milliliters \[mL\]). Participants whose virus ribonucleic acid (RNA) did not reach the limit by the last observation timepoint were treated as censored at that timepoint. Median time was estimated using K-M method.
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Time to Cessation of Viral Shedding by Virus Titer | 23.2 (21.9 to 24.4) | 100.7 (70.9 to 120.3) |
Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of study treatment and the first time when the virus RNA by RT-PCR qualitative result is below the LLoD (qualitative assessment). For the participants with multiple virus types, time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA by RT-PCR qualitative result is negative for all virus types. Participants whose virus RNA did not reach the limit by the last observation timepoint were censored at that timepoint. Median time was estimated using K-M method.
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Time to Cessation of Viral Shedding by Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) Using Samples From Respiratory Swabs | 218.4 (214.8 to 242.7) | 238.6 (214.8 to NA) |
Change from baseline in influenza virus titer (log10 TCID50/mL) on Days 2, 4, 6, 10, and 15 are presented. Influenza virus titer on specified time points was analysed with use of samples from respiratory swabs. If influenza virus titer was less than the lower limit of quantification (LLoQ), the virus titer was imputed as LLoQ - 0.001 (0.749 log10 TCID50/mL). Only participants with a positive virus titer on Day 1 were included in this analysis.
| log10 TCID 50/mL | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Baseline | 4.41 ± 1.32 | 5.21 ± 1.11 |
| Change at Day 2 | -3.61 ± 1.45 | -3.11 ± 1.34 |
| Change at Day 4 | -3.65 ± 1.35 | -3.06 ± 1.85 |
| Change at Day 6 | -3.72 ± 1.43 | -4.30 ± 1.13 |
| Change at Day 10 | -3.95 ± 1.28 | -4.50 ± 1.09 |
| Change at Day 15 | — | -5.50 ± NA |
If the amount of virus RNA was less than the LLoQ, the amount of virus RNA was imputed as LLoQ - 0.001 (2.79 log10 vp/mL for influenza A and 2.63 log10 vp/mL for influenza B). If a participant was infected with multiple virus types, the sum of those amounts of virus RNA was used for analysis. Participants positive for virus RNA by RT-PCR on Day 1 were included in this analysis. log10 vp/mL=log 10 virus particles per milliliter.
| log10 vp/mL | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Baseline | 7.00 ± 1.25 | 7.43 ± 1.20 |
| Change at Day 2 | -1.76 ± 1.37 | -1.37 ± 0.77 |
| Change at Day 4 | -2.79 ± 1.39 | -1.82 ± 1.71 |
| Change at Day 6 | -2.92 ± 1.44 | -2.81 ± 1.69 |
| Change at Day 10 | -4.04 ± 1.34 | -3.70 ± 1.28 |
| Change at Day 15 | — | -4.64 ± NA |
Percentage of participants with positive influenza virus titer was defined as the percentage of participants whose influenza virus titer was not less than the LLoD (0.75 log10 TCID50/mL) or positive among those assessed for influenza virus titer on specified timepoints. Analyses were done with use of samples from respiratory swabs. Participants with a positive influenza virus titer on Day 1 were be included in this analysis. Percentages have been rounded off.
| percentage of participants | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Baseline | 100.0 | 100.0 |
| Day 2 | 11.1 | 85.7 |
| Day 4 | 6.0 | 65.4 |
| Day 6 | 10.0 | 13.6 |
| Day 10 | 3.4 | 0 |
| Day 15 | — | 0 |
Percentage of participants with positive influenza virus titer was defined as the percentage of participants with a positive qualitative result among those assessed by RT-PCR on specified timepoints. Analyses were done with use of samples from respiratory swabs. Participants positive for virus RNA by RT-PCR on Day 1 were be included in this analysis. Percentages have been rounded off.
| percentage of participants | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Baseline | 100.0 | 100.0 |
| Day 2 | 98.3 | 100.0 |
| Day 4 | 91.4 | 96.4 |
| Day 6 | 82.7 | 92.0 |
| Day 10 | 51.7 | 59.3 |
| Day 15 | — | 100.0 |
AUC was calculated using the trapezoidal method. Participants with a positive virus titer on Day 1 were included in this analysis. The lower limit was defined as 0.75 log10 TCID50/mL for flu A and flu B. If a participant was infected with multiple virus types, the sum of those virus titers was used for analysis. log10 TCID50/mL\*h=log10 TCID50 per milliliter-hours. Analyses were done with use of samples from respiratory swabs.
| log10 TCID 50/mL*h | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Area Under the Curve (AUC) in Virus Titer | -536.09 ± 312.86 | -610.11 ± 414.54 |
AUC in virus RNA (RT-PCR) AUC was calculated using the trapezoidal method. Participants positive for virus RNA by RT-PCR on Day 1 were included in this analysis. If a participant was infected with multiple virus types, the sum of the amount of virus RNA was used for analysis. log10 vp/mL\*h=log 10 virus particles per milliliter-hours.
| log10 vp/mL*h | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| AUC in the Amount of Virus RNA (RT-PCR) Using Samples From Respiratory Swabs | -390.08 ± 263.39 | -388.13 ± 325.99 |
S-033447 is an active metabolite of baloxavir marboxil.
| nanograms per milliliter (ng/mL) | Baloxavir Marboxil |
|---|---|
| Post-dose Day 1 | 75.49 ± 77.283 |
| Post-dose Day 2 | 125.25 ± 35.225 |
| Post-dose Day 4 | 43.15 ± 24.872 |
| Post-dose Day 6 | 15.86 ± 9.169 |
S-033447 is an active metabolite of baloxavir marboxil.
| nanograms-hour per milliliter (ng*h/mL) | Baloxavir Marboxil |
|---|---|
| Bodyweight <20 kg, Dose=2 mg/kg | 9550 ± 4230 |
| Bodyweight ≥20 kg, Dose=40 mg | 11800 ± 4870 |
S-033447 is an active metabolite of baloxavir marboxil.
| ng/mL | Baloxavir Marboxil |
|---|---|
| Bodyweight <20 kg, Dose=2 mg/kg | 182 ± 68.2 |
| Bodyweight ≥20 kg, Dose=40 mg | 159 ± 72.2 |
S-033447 is an active metabolite of baloxavir marboxil.
| hours | Baloxavir Marboxil |
|---|---|
| Bodyweight <20 kg, Dose=2 mg/kg | 3.75 (1.00 to 15.0) |
| Bodyweight ≥20 kg, Dose=40 mg | 4.25 (1.00 to 15.5) |
S-033447 is an active metabolite of baloxavir marboxil.
| hours | Baloxavir Marboxil |
|---|---|
| Bodyweight <20 kg, Dose=2 mg/kg | 30.0 (21.8 to 56.0) |
| Bodyweight ≥20 kg, Dose=40 mg | 45.8 (31.0 to 91.4) |
Sanger sequencing of the influenza PA gene was performed to evaluate the incidence of polymorphic and treatment-emergent amino acid substitutions in baloxavir-treated participants with evaluable virus.
| percentage of participants | Influenza Type A/H1_2009 | Influenza Type A/H3N2 | Influenza Type B |
|---|---|---|---|
| Percentage of Participants With Polymorphic and Treatment-emergent Amino Acid Substitutions in the Polymerase Acidic (PA) Gene | 10.64 (3.55 to 23.10) | 100.00 (15.81 to 100.00) | 0.00 (0.00 to 84.19) |
Drug susceptibility of the influenza virus, the 50% effective concentration (EC50) of baloxavir was measured by the ViroSpot™ assay using baseline swab samples for participants who received baloxavir marboxil. EC50 values were compared with EC50 values of reference strains and the respective ratio (EC50 / EC50 reference) was reported. The following influenza virus vaccines strains from the 2024/25 Northern hemisphere season were used as references: A/Wisconsin/67/2022 (H1N1) pdm09-like virus, A/Massachusetts/18/2022 (H3N2)-like virus and B/Austria/1359417/2021-like virus (B/Victoria/2/87 lineage). In the absence of established thresholds for baloxavir, reduced susceptibility was defined according to the WHO criteria for neurainidase inhibitor (NAI) as fold-changes in EC50 (EC50 / EC50 of reference) \> 10 for influenza A and \> 5 for influenza B viruses.
| ratio | Baloxavir Marboxil |
|---|---|
| Virus Subtype B | 4.224 ± 0.3019 |
| Virus Subtype H1_2009 | 2.226 ± 0.6764 |
| Virus Subtype_H3 | 1.904 ± 1.5768 |
A two-question palatability and acceptability questionnaire was used to record palatability and acceptability. Palatability of baloxavir marboxil was evaluated by response to the following question, "How was the taste of the medicine? Please pick the face that best matches how you/the child felt about the taste". The responses ranged from: like very much, like a little, not sure, dislike a little, or dislike very much. Acceptability of baloxavir marboxil was evaluated by response to the following question, "Would you/the child be happy to take the medicine again?" The responses ranged from: Yes, No, or Not sure. The questionnaire was completed as soon as possible after swallowing the baloxavir marboxil drug solution on Day 1. Percentages have been rounded off.
| percentage of participants | Baloxavir Marboxil |
|---|---|
| Palatability: Like Very Much | 39.4 |
| Palatability: Like a Little | 31.8 |
| Palatability: Not Sure | 6.1 |
| Palatability: Dislike a Little | 18.2 |
| Palatability: Dislike Very Much | 4.5 |
| Acceptability: Yes | 65.2 |
| Acceptability: No | 16.7 |
| Acceptability: Not Sure | 18.2 |
Collected over Up to Day 29. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baloxavir Marboxil | 0/66 (0%) | 2/66 (3%) | 14/66 (21.2%) |
| Oseltamivir | 0/33 (0%) | 0/33 (0%) | 10/33 (30.3%) |
| Event | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| PneumoniaInfections and infestations | 1/66 | 0/33 |
| Pneumonia mycoplasmalInfections and infestations | 1/66 | 0/33 |
| Event | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| VomitingGastrointestinal disorders | 3/66 | 6/33 |
| BronchitisInfections and infestations | 5/66 | 0/33 |
| Functional gastrointestinal disorderGastrointestinal disorders | 2/66 | 2/33 |
| RhinitisInfections and infestations | 0/66 | 2/33 |
| Upper respiratory tract infectionInfections and infestations | 4/66 | 1/33 |
FAS included all randomized participants, with participants grouped according to the treatment assigned.
| Age, Continuous(years) | Baloxavir Marboxil | Oseltamivir | Total |
|---|---|---|---|
| Mean | 5.1 ± 2.55 | 5.3 ± 2.75 | 5.2 ± 2.61 |
| Sex: Female, Male(Participants) | Baloxavir Marboxil | Oseltamivir | Total |
|---|---|---|---|
| Female | 34 | 11 | 45 |
| Male | 33 | 22 | 55 |
| Ethnicity (NIH/OMB)(Participants) | Baloxavir Marboxil | Oseltamivir | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 67 | 33 | 100 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Baloxavir Marboxil | Oseltamivir | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 67 | 33 | 100 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Oct 2024 to primary completion in May 2025, 6 months.
Results were first posted in Apr 2026, 11 months after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 6 months is below that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baloxavir